Drug Costs
101-120 of 705 results
-
-
What Would a Second Trump Presidency Look Like for Health Care?
Health policy during Donald Trump鈥檚 tenure was dominated by covid-19 and a failed effort to repeal and replace the Affordable Care Act. His appointments to the Supreme Court led to the end of national abortion rights, and he took steps to increase hospital price transparency and improve care for veterans.
By Julie Rovner 2023 Is a Wrap
Episode 3272023 was another busy year in health care. As the covid-19 pandemic waned, policymakers looked anew at long-standing obstacles to obtaining and paying for care in the nation鈥檚 health care system. Meanwhile, abortion has continued to be an issue in much of the nation, as states respond to the Supreme Court鈥檚 2022 decision overturning the constitutional right to the procedure. This week, Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of Johns Hopkins University and Politico Magazine join 杨贵妃传媒視頻 Health News chief Washington correspondent Julie Rovner to discuss these issues and wrap up the year in health. Also this week, Rovner interviews 杨贵妃传媒視頻 Health News鈥 Jordan Rau about his joint 杨贵妃传媒視頻 Health News-New York Times series 鈥淒ying Broke.鈥
-
A New Test Could Save Arthritis Patients Time, Money, and Pain. But Will It Be Used?
Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.
By Arthur Allen -
Colorado Blames Biden Team and Drugmakers for Delaying Canadian Imports
Colorado officials say they haven鈥檛 been able to stand up a program to import drugs from Canada because of drugmaker opposition 鈥 and the Biden administration鈥檚 inaction.
-
-
Health Care Is Front and Center as DeSantis and Newsom Go Mano a Mano
Florida鈥檚 Republican Gov. Ron DeSantis and California鈥檚 Democratic Gov. Gavin Newsom will square off in a first-of-its-kind debate on Nov. 30. 杨贵妃传媒視頻 Health News compared the political rivals鈥 health care positions, showing how their policies have helped 鈥 or hindered 鈥 the health of their states鈥 residents.
By Daniel Chang and Angela Hart -
Beyond Insulin: Medi-Cal Expands Patient Access to Diabetes Supplies
California鈥檚 Medicaid program is making it easier for people with diabetes to obtain the supplies and equipment they need to manage their blood sugar, partly by relaxing preauthorization requirements that can cause life-threatening delays.
By Angela Hart John Green vs. Johnson & Johnson (Part 2)
Season 10, Episode 3The high price of lifesaving tuberculosis drugs makes them inaccessible to many who need them most. On this episode of 鈥淎n Arm and a Leg,鈥 hear how a decades-long global fight to reform drug patents is helping to lower the cost.
-
News Analysis
A New Era of Vaccines Leaves Old Questions About Prices Unanswered
The CDC鈥檚 RSV vaccination recommendations beg the question: How much should an immunization that will possibly be given to millions of Americans cost to be truly valuable?
-
Postcard from Capitol Hill
Biden Pick to Lead NIH Finally Has Her Day, but Still Gets Caught Up in Drug Price Debate
Monica Bertagnolli, the president鈥檚 choice to head the National Institutes of Health, appeared before a Senate committee this week. Her confirmation has been held up by Sen. Bernie Sanders (I-Vt.), who has demanded President Joe Biden work more aggressively to lower prescription drug prices.
Health Funding in Question in a Speaker-Less Congress
Episode 318A bitterly divided Congress managed to keep the federal government running for several more weeks, while House Republicans struggle 鈥 again 鈥 to choose a leader. Meanwhile, many people removed from state Medicaid rolls are not finding their way to Affordable Care Act insurance, and a major investigation by The Washington Post attributes the decline in U.S. life expectancy to more than covid-19 and opioids. Lauren Weber of The Washington Post, Victoria Knight of Axios, and Sarah Karlin-Smith of the Pink Sheet join 杨贵妃传媒視頻 Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews physician-author-playwright Samuel Shem about 鈥淥ur Hospital,鈥 his new novel about the health workforce in the age of covid.
John Green vs. Johnson & Johnson (Part 1)
Season 10, Episode 2Pharmaceutical patents can drive up the costs of lifesaving medications. Hear what author and YouTube star John Green is doing to make tuberculosis drugs more accessible to the people who need them most.
Countdown to Shutdown
Episode 315Congress appears to be careening toward a government shutdown, as a small band of House conservatives vow to block any funding for the fiscal year that begins Oct. 1 unless they win deeper cuts to health and other domestic programs. Meanwhile, former President Donald Trump continues to roil the GOP presidential primary field, this time with comments about abortion. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Tami Luhby of CNN join 杨贵妃传媒視頻 Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also, for 鈥渆xtra credit,鈥 the panelists suggest health policy stories they read this week they think you should read, too.
-
Hep C鈥檚 Number Comes Up: Can Biden鈥檚 5-Year Plan Eliminate the Longtime Scourge?
Before covid-19, hepatitis C held the distinction of claiming more American lives each year than any other infectious disease 鈥 that鈥檚 despite the marketing of several relatively affordable, highly effective treatments.
-
Save Billions or Stick With Humira? Drug Brokers Steer Americans to the Costly Choice
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.
By Arthur Allen Welcome Back, Congress. Now Get to Work.聽
Episode 313Congress returns from its summer recess with a long list of tasks and only a few work days to get them done. On top of the annual spending bills needed to keep the government operating, on the list are bills to renew the global HIV/AIDS program, PEPFAR, and the community health centers program. Meanwhile, over the recess, the Biden administration released the names of the first 10 drugs selected for the Medicare price negotiation program.
-
A Move to Cut Drug Prices Has Patients With Rare Diseases Worried
A Colorado board has named five drugs it will review for affordability and potential cost caps. But patients with cystic fibrosis worry they will lose access to a life-changing therapy.
-
5 Things to Know About the New Drug Pricing Negotiations
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
-
News Analysis
A Peek at Big Pharma鈥檚 Playbook That Leaves Many Americans Unable to Afford Their Drugs
Brand-name drug prices in the U.S. 鈥 more than three times the price in other developed countries 鈥 are related neither to the amount of research and development required to bring them to market nor their therapeutic value, recent research shows. Have drugmakers overplayed their hand?